Portfolio Composition Clause Samples

Portfolio Composition. The Adviser shall provide (or cause the Trust's custodian to provide) timely information to the Sub-Adviser regarding such matters as the composition of the Assets and cash available for investment in the Fund and cash requirements (with respect to the redemption of Fund shares) and such other information as the parties may reasonably agree upon.
View SourceView Similar (6)
Portfolio Composition. Our portfolio companies are primarily privately held companies and public companies which are active in the drug discovery and development, energy technology, internet consumer and business services, medical device and equipment, software, drug delivery, specialty pharmaceuticals, communications and networking, media/content/info, healthcare services, information services, surgical devices, semiconductors, biotechnology tools, consumer and business products, diagnostic and electronics and computer hardware industry sectors. These sectors are characterized by high margins, high growth rates, consolidation and product and market extension opportunities. Value for companies in these sectors is often vested in intangible assets and intellectual property. As of March 31, 2014, approximately 64.9% of the fair value of our portfolio was composed of investments in four industries: 23.2% was composed of investments in the drug discovery and development industry, 18.7% was composed of investments in the energy technology industry, 11.9% was composed of investments in the internet consumer and business services industry and 11.1% was composed of investments in the medical device and equipment industry. The following table shows the fair value of our portfolio by industry sector at March 31, 2014 (unaudited) and December 31, 2013: March 31, 2014 December 31, 2013 (in thousands) Investments at Fair Value Percentage of Total Portfolio Investments at Fair Value Percentage of Total Portfolio Drug Discovery & Development $ 206,535 23.2% $ 219,169 24.1% Energy Technology 166,482 18.7% 164,466 18.1% Internet Consumer & Business Services 105,964 11.9% 122,073 13.4% Medical Devices & Equipment 99,061 11.1% 103,614 11.4% Software 79,077 8.9% 65,218 7.2% Drug Delivery 63,335 7.1% 62,022 6.8% Specialty Pharmaceuticals 40,217 4.5% 20,055 2.2% Communications & Networking 35,526 4.0% 35,979 4.0% Media/Content/Info 29,447 3.3% 8,679 1.0% Healthcare Services, Other 20,626 2.3% 29,080 3.2% Information Services 15,102 1.7% 46,565 5.1% Surgical Devices 10,353 1.1% 10,307 1.0% Semiconductors 9,464 1.1% 4,685 0.5% Biotechnology Tools 4,541 0.5% 5,275 0.6% Consumer & Business Products 3,282 0.4% 2,995 0.3% Diagnostic 858 0.1% 902 0.1% Electronics & Computer Hardware 792 0.1% 9,211 1.0% $ 890,662 100.0% $ 910,295 100.0% Industry and sector concentrations vary as new loans are recorded and loans pay off. Loan revenue, consisting of interest, fees, and recognition of gains on equity and equity...
View SourceView Similar (4)
Portfolio Composition. Without in any way limiting the ability of the --------------------- Company and its advisors to invest in specific assets and once the Company is fully invested, the Company and its advisors will seek, in making investments in real estate assets or real estate related assets, to maintain a portfolio composition which will generally further the aims of the Company, such as maintaining its status as a real estate investment trust and generating current income and long term gains.
View SourceView Similar (2)
Portfolio Composition. Our portfolio companies are primarily privately held companies and public companies which are active in the software, drug discovery & development, internet consumer & business services, sustainable and renewable technology, drug delivery, healthcare services, medical devices & equipment, media/content/info, diversified financial services, information services, electronics & computer hardware, consumer & business products, surgical devices, communications & networking, biotechnology tools, semiconductors, diagnostic and specialty pharmaceuticals industry sectors. These sectors are characterized by high margins, high growth rates, consolidation and product and market extension opportunities. Value for companies in these sectors is often vested in intangible assets and intellectual property. As of March 31, 2018, approximately 78.1% of the fair value of our portfolio was composed of investments in five industries: 26.5% investments in the software industry, 26.1% investments in the drug discovery & development industry, 12.0% investments in the internet consumer & business services industry, 7.8% investments in the sustainable and renewable technology industry, and 5.7% investments in the drug delivery. Industry and sector concentrations vary as new loans are recorded and loans pay off. Loan revenue, consisting of interest, fees, and recognition of gains on equity and warrants or other equity-related interests, can fluctuate materially when a loan is paid off or a warrant or equity interest is sold. Revenue recognition in any given year can be highly concentrated in several portfolio companies. For the three months ended March 31, 2018 and the year ended December 31, 2017, our ten largest portfolio companies represented approximately 29.7% and 34.6% of the total fair value of our investments in portfolio companies, respectively. At March 31, 2018 and December 31, 2017, we had five and seven investments, respectively, that represented 5% or more of our net assets. At March 31, 2018, we had seven equity investments representing approximately 64.9% of the total fair value of our equity investments, and each represented 5% or more of the total fair value of our equity investments. At December 31, 2017, we had nine equity investments which represented approximately 67.1% of the total fair value of our equity investments, and each represented 5% or more of the total fair value of our equity investments. As of March 31, 2018, approximately 96.5% of the debt investm...
View SourceView Similar (2)
Portfolio Composition. Our portfolio companies are primarily privately held companies and public companies which are active in the drug discovery and development, medical device and equipment, software, internet consumer and business services, energy technology, drug delivery, specialty pharmaceuticals, communications and networking, media/content/info, consumer and business products, information services, surgical devices, healthcare services, semiconductors, biotechnology tools, diagnostic and electronics and computer hardware industry sectors. These sectors are characterized by high margins, high growth rates, consolidation and product and market extension opportunities. Value for companies in these sectors is often vested in intangible assets and intellectual property. As of September 30, 2014, approximately 68.9% of the fair value of our portfolio was composed of investments in five industries: 23.2% was composed of investments in the drug discovery and development industry, 13.9% was composed of investments in the medical devices and equipment industry, 11.3% was composed of investments in the software industry, 10.6% was composed of investments in the internet consumer and business services industry and 9.9% was composed of investments in the energy technology industry. The following table shows the fair value of our portfolio by industry sector at September 30, 2014 (unaudited) and December 31, 2013: Drug Discovery & Development $ 232,214 23.2% $ 219,169 24.1% Medical Devices & Equipment 139,154 13.9% 103,614 11.4% Software 112,503 11.3% 65,218 7.2% Internet Consumer & Business Services 106,128 10.6% 122,073 13.4% Energy Technology 98,555 9.9% 164,466 18.1% Drug Delivery 83,247 8.3% 62,022 6.8% Specialty Pharmaceuticals 73,127 7.3% 20,055 2.2% Communications & Networking 56,292 5.6% 35,979 4.0% Media/Content/Info 29,361 2.9% 8,679 1.0% Consumer & Business Products 25,309 2.5% 2,995 0.3% Information Services 14,917 1.5% 46,565 5.1% Surgical Devices 9,822 1.0% 10,307 1.0% Healthcare Services, Other 7,666 0.8% 4,685 0.5% Semiconductors 5,354 0.6% 29,080 3.2% Biotechnology Tools 3,894 0.4% 5,275 0.6% Diagnostic 775 0.1% 902 0.1% Electronics & Computer Hardware 595 0.1% 9,211 1.0% $ 998,913 100.0% $ 910,295 100.0% Industry and sector concentrations vary as new loans are recorded and loans pay off. Loan revenue, consisting of interest, fees, and recognition of gains on equity and equity- related interests, can fluctuate materially when a loan is paid off or a related warrant o...
View Source

Related to Portfolio Composition

  • Board Composition Each Holder agrees to vote, or cause to be voted, all Shares owned by such Holder, or over which such Holder has voting control, from time to time and at all times, in whatever manner as shall be necessary to ensure that at each annual or special meeting of stockholders at which an election of directors is held or pursuant to any written consent of the stockholders, subject to Section 5, the following persons shall be elected to the Board: (a) As the Series A Director, one person designated from time to time by a majority of the holders of Series A Preferred Stock (the “Series A Designee”), for so long as 1,000,000 share of Series A Preferred Stock are outstanding, which number is subject to appropriate adjustment for any stock splits, stock dividends, combinations, recapitalizations and the like, which individual shall initially be ▇▇. ▇▇▇▇▇▇▇ ▇▇▇▇▇▇; (b) As the Common Stock Director, one person designated from time to time by a majority of the holders of Common Stock (the “Common Stock Designees”), which individual shall initially be ▇▇▇▇ ▇▇▇▇▇▇▇▇▇; and (c) The Company’s Chief Executive Officer, who as of the date of this Agreement is ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇ M.D. (the “CEO Director”), provided that if for any reason the CEO Director shall cease to serve as the Chief Executive Officer of the Company, each of the Holders shall promptly vote their respective Shares (i) to remove the former Chief Executive Officer of the Company from the Board if such person has not resigned as a member of the Board; and (ii) to elect such person’s replacement as Chief Executive Officer of the Company as the new CEO Director. To the extent that any of clauses (a) through (c) above shall not be applicable, any member of the Board who would otherwise have been designated in accordance with the terms thereof shall instead be voted upon by all the Holders of the Company entitled to vote thereon in accordance with, and pursuant to, the Restated Certificate. For purposes of this Agreement, an individual, firm, corporation, partnership, association, limited liability company, trust or any other entity (collectively, a “Person”) shall be deemed an “Affiliate” of another Person who, directly or indirectly, controls, is controlled by or is under common control with such Person, including, without limitation, any general partner, managing member, officer, director or trustee of such Person, or any venture capital fund or registered investment company now or hereafter existing that is controlled by one (1) or more general partners, managing members or investment advisers of, or shares the same management company or investment adviser with, such Person.

  • Formation and Composition The Parties to this agreement will maintain a Joint Administration and Dispute Resolution Committee (JADRC) consisting of five (5) representatives of the employers and five (5) representatives of the Provincial Bargaining Council.

  • Diagnostic procedures to aid the Provider in determining required dental treatment.

  • Compositions any corporate action, legal proceedings or other procedures or steps are taken, or negotiations commenced, by any Security Party or by any of its creditors with a view to the general readjustment or rescheduling of all or part of its Indebtedness or to proposing any kind of composition, compromise or arrangement involving such company and any of its creditors; or

  • Licensed Product The term “Licensed Product” shall mean any product (a) the manufacture, use, importation, sale or offer for sale of which would, in the absence of the license granted by this Agreement, infringe a Valid Claim of any of the Licensed Patent Rights, or (b) that is comprised of, utilizes or incorporates Licensed Biological Materials, or (c) that is discovered, developed or made using a Licensed Process.